RBC Capital Maintains Outperform on OptimizeRx, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Sean Dodge has maintained an Outperform rating on OptimizeRx (NASDAQ:OPRX) and increased the price target from $14 to $17, indicating a positive outlook on the company's stock.
January 10, 2024 | 3:03 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital analyst Sean Dodge has reaffirmed an Outperform rating on OptimizeRx and raised the price target from $14 to $17, suggesting confidence in the company's future performance.
The increase in price target by a reputable analyst like Sean Dodge from RBC Capital typically signals a bullish outlook on the stock, which can positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100